Acromegaly: What IGF-1 and GH Reveal About Growth Drive

Understand what your hormone testing results really mean

See your biomarkers in context with a comprehensive panel.

• CLIA-certified labs
• HIPAA compliant
• Personalized health protocol

Book your test

What acromegaly is, and the growth signal behind it

Acromegaly is a condition in which the body keeps making too much growth hormone after adulthood, almost always because a benign tumor in the pituitary gland will not stop signaling. The excess builds slowly, thickening bone and soft tissue over years, and it registers in blood as a raised IGF-1.

Growth hormone rarely acts alone. It instructs the liver to release insulin-like growth factor 1 (IGF-1), and IGF-1 carries most of the growth message to the tissues. When that message runs continuously, cartilage, bone, skin, and internal organs keep responding to a request the body stopped making decades ago.

You will see the same condition described in other words: growth hormone excess, a somatotropinoma, or a GH-secreting pituitary adenoma. They all name the same underlying problem, and they all trace back to one small gland at the base of the brain.

How growth hormone and IGF-1 actually differ

Growth hormone and IGF-1 answer different questions. Growth hormone is released in short bursts through the day and night, so a single random draw can look entirely ordinary in someone whose disease is active. IGF-1 barely moves hour to hour, which makes it a running average of how much growth signaling the tissues have absorbed.

That stability is why IGF-1, not growth hormone, is the first test used to screen for acromegaly. A one-off growth hormone value is only informative under controlled conditions, which is exactly what the confirmatory suppression test creates. Put simply: growth hormone is the transmitter, and IGF-1 is the record of what was transmitted.

Acromegaly vs gigantism: what separates them

Same hormone problem, different timing. Growth hormone excess that begins before the growth plates fuse pushes the long bones to keep lengthening, producing gigantism and unusual height. The same excess after the plates close cannot add length, so bone widens and thickens instead. That is acromegaly.

| | Gigantism | Acromegaly | |---|---|---| | Age of onset | Childhood or adolescence | Adulthood, most often diagnosed in the fifth decade | | Growth plates | Still open | Fused | | Effect on height | Marked increase in height | Height unchanged | | Underlying cause | Growth hormone excess, usually pituitary | Growth hormone excess, usually pituitary | | Typical presentation | Rapid linear growth, delayed puberty | Enlarging hands and feet, coarsening features | | Genetic contribution | Frequent, including AIP mutations and X-LAG | Uncommon |

Genetics matter far more at the younger end. In an international series of 208 people with pituitary gigantism, AIP mutations accounted for 29% of patients, with X-linked acrogigantism explaining a smaller subset, which is why early-onset growth hormone excess usually prompts genetic evaluation.

What early acromegaly looks like before anyone names it

The earliest clues are usually about objects, not about the body. Nobody notices their own face changing that slowly, but everyone notices a ring that stopped sliding off.

• A wedding ring that no longer fits, or has been resized more than once
• Shoe size creeping up well into adulthood
• New gaps opening between the teeth, or a bite that feels different
• Hats, gloves, or glasses frames that have grown tight
• New or louder snoring, and waking up unrested
• Numbness or tingling in the hands at night
• Sweating more than you used to, particularly overnight
• A voice that has deepened, alongside headaches that keep returning

Individually, none of these send anyone to an endocrinologist. Together, and over years, they are the reason acromegaly is so often identified late. Diagnosis commonly arrives long after the first changes begin, and a longer delay tracks with more comorbidity and higher mortality. Old photographs are frequently the most persuasive evidence in the room.

Join 150,000+ others building better health

Get the science behind better health, every week.

SubscribeSigning up...

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

Where excess growth hormone shows up in the body

Growth hormone receptors sit almost everywhere, so acromegaly is never confined to one system. Three groupings capture most of what people experience.

Face, hands, and feet

• Broader hands and thicker fingers, and feet up a half or full shoe size
• A more prominent brow and jaw, with wider spacing between the teeth
• An enlarged tongue, thicker lips, and a broader nose

Skin, joints, and soft tissue

• Thickened, oilier skin and an increase in skin tags
• Joint pain and stiffness as cartilage overgrows, most often in the knees, hips, shoulders, and hands
• Carpal tunnel symptoms as soft tissue swelling compresses the median nerve
• A deeper voice from thickened vocal cords, and enlargement of internal organs

Heart, lungs, and metabolism

• Raised blood pressure and thickening of the heart muscle, alongside the higher rates of atrial fibrillation and heart failure seen in acromegaly
• Obstructive sleep apnea, driven by soft tissue crowding the upper airway
• Insulin resistance, because growth hormone directly opposes insulin's action
• Secondary diabetes, one of the most common metabolic consequences of sustained growth hormone excess

These are the complications that make earlier detection worth something. They accumulate quietly, and the cardiovascular, respiratory, and metabolic burden is what drives long-term outcomes far more than appearance does.

What drives the growth hormone excess in acromegaly

Pituitary somatotroph adenomas

A benign tumor of the pituitary's growth hormone cells accounts for more than 95% of acromegaly cases. These adenomas are not cancer, and they rarely spread. What they do is ignore the body's off switch.

Size shapes the picture. Adenomas 10 millimeters or smaller are called microadenomas and usually announce themselves only through the hormone excess. Larger macroadenomas can also press on neighboring structures, causing headaches, loss of peripheral vision, and reduced output of other pituitary hormones. Some of these tumors co-secrete prolactin, which is why a raised prolactin sometimes appears alongside a raised IGF-1.

Rare causes outside the pituitary

A small minority of cases start elsewhere. Neuroendocrine tumors of lung or pancreatic origin can secrete growth hormone-releasing hormone (GHRH), which stimulates a normal pituitary into overproduction. Inherited syndromes account for another slice, including AIP mutations in familial isolated pituitary adenoma, multiple endocrine neoplasia type 1, McCune-Albright syndrome, and X-linked acrogigantism. These rarer routes to growth hormone excess matter clinically because they change who else in a family may warrant testing.

Who is most likely to develop acromegaly

Acromegaly is genuinely rare. Population studies place the prevalence at 2.8 to 13.7 cases per 100,000 people, with 0.2 to 1.1 new diagnoses per 100,000 people each year. It affects men and women at broadly similar rates.

Most people are diagnosed in the fifth decade of life, though the hormone excess typically started years earlier. Two groups deserve earlier attention: anyone with a pituitary lesion found incidentally on brain imaging, and anyone with a family history of pituitary tumors or a known genetic syndrome. In those families, growth hormone excess tends to appear at a younger age and can be caught before the structural changes set in.

The three steps that confirm an acromegaly diagnosis

The biochemical pathway is short and has stayed remarkably stable:

1. Screen with an IGF-1 measured against an age- and sex-specific range.
2. Confirm with a growth hormone suppression test during an oral glucose load.
3. Localize the source with a pituitary MRI.

The IGF-1 blood test

IGF-1 is a single venous draw. No fasting is required, and the time of day does not matter, because IGF-1 does not pulse the way growth hormone does. A clearly normal age-adjusted IGF-1 makes active acromegaly unlikely, and a persistently raised one is what moves the workup forward.

The glucose suppression test

In healthy physiology, a sugar load switches growth hormone off. The test uses that reflex: after a 75-gram oral glucose load, growth hormone is sampled repeatedly over the next two hours. Failure to suppress below the assay's threshold, historically around 1 microgram per liter, supports the diagnosis. Current consensus reserves the test for patients whose baseline hormone levels do not clarify the diagnosis.

Pituitary MRI and follow-on screening

Imaging comes after the biochemistry, not before it, because pituitary incidentalomas are common and mean little without hormonal evidence. An MRI with contrast locates the adenoma and sizes it, which informs what happens next.

Once acromegaly is established, clinicians typically look for the complications it tends to bring: an echocardiogram, a sleep study, glucose and HbA1c testing, and colonoscopy, given the increased rate of colonic polyps and colorectal cancer in this group.

| Test | What it measures | What an out-of-range result looks like | When it is used | |---|---|---|---| | IGF-1 | Average growth hormone action over recent weeks | Above the age- and sex-specific upper limit | First-line screening and all follow-up | | Growth hormone suppression test | Whether glucose switches growth hormone off | Growth hormone stays above the nadir threshold | Confirmation after a raised IGF-1 | | Pituitary MRI | Presence, size, and position of an adenoma | A visible pituitary mass, micro or macro | After biochemical confirmation | | Random growth hormone | One point in a pulsatile rhythm | Unreliable in isolation | Rarely, and never alone | | Prolactin | Co-secretion by the same tumor | Raised alongside IGF-1 | Part of a full pituitary workup |

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your testLoading...

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your testLoading...

Reading an IGF-1 result against your range

An IGF-1 number means nothing without an age. Levels peak during adolescence and fall steadily across adult life, so every result is read against a range built for your age and sex, and many laboratories report it as a standard deviation score rather than raw nanograms per milliliter. What decides the acromegaly question is not simply being high, but how far above the ceiling a result sits and whether it stays there.

| IGF-1 result | What it suggests | Typical next step | |---|---|---| | Clearly within the age- and sex-adjusted range | Active acromegaly is unlikely | No further growth hormone workup unless symptoms persist | | Near the top of the range, or borderline | Equivocal, and assay-dependent | Repeat on the same assay, with clinical correlation | | Above the upper limit | Sustained growth hormone excess is likely | Growth hormone suppression testing | | More than 1.3 times the upper limit for age | Supports the diagnosis when typical features are present | Pituitary imaging and specialist referral |

One practical caveat carries real weight: IGF-1 assays are not yet comparable across methods. Differences in method and calibration mean the same sample can return meaningfully different numbers in two labs, which is why repeat measurements should use the same validated assay. A number that appears to have shifted may just have changed laboratories.

What else moves IGF-1 during an acromegaly workup

Acromegaly is not the only reason IGF-1 sits outside its range. Puberty, pregnancy, and growth hormone therapy push it up; aging, malnutrition or severe calorie restriction, liver and kidney disease, poorly controlled diabetes, untreated hypothyroidism, and oral estrogen pull it down. The full set of influences, and what each one does to a result, is mapped in the guide to IGF-1 and its reference ranges.

Two situations change how this particular workup reads. A raised IGF-1 in someone using exogenous growth hormone or a secretagogue peptide reflects what they are taking, not a pituitary adenoma, and disclosure changes the interpretation entirely. At the opposite end, a persistently low IGF-1 points away from acromegaly and toward reduced growth hormone action, though a normal result cannot rule that out on its own.

When acromegaly gets tested and retested

Testing is usually triggered by one of three situations:

• A cluster of features appearing together, such as enlarging hands or feet, changed facial structure, and new carpal tunnel symptoms
• A pituitary lesion discovered incidentally on brain imaging performed for another reason
• An unexplained convergence of sleep apnea, hypertension, and insulin resistance in the same person, particularly at a younger age than expected

After treatment, IGF-1 becomes the tracking marker rather than the screening one. In the first year after surgery it is typically rechecked every 3 to 6 months to confirm remission, then every 6 to 12 months to watch for recurrence. The goal of monitoring is an IGF-1 that has returned into the range for your age, which is how biochemical control is defined.

What changes after growth hormone levels come down

Not everything returns to how it was, and being honest about that is part of understanding the condition.

Soft tissue responds first. Swelling in the hands and face recedes, rings and shoes often fit again, excessive sweating settles, headaches ease, and carpal tunnel symptoms frequently improve within months. Sleep apnea severity tends to improve after treatment for acromegaly, and glucose handling commonly improves alongside it.

Bone does not go back. Changes to the jaw, brow, hands, and feet are structural and permanent, as is established joint damage. What controlling the hormone does change is the trajectory: mortality has moved toward general-population levels as biochemical control has become more achievable. Acromegaly is not something lifestyle causes, and nothing in a daily routine lowers the likelihood of it, which is exactly why recognizing the pattern early is where the value sits.

Track your IGF-1 and hormone biomarkers with a Superpower panel

Acromegaly is rare, but the axis behind it is worth understanding for anyone paying attention to hormonal health. IGF-1 sits at the intersection of growth, metabolism, and aging, and it is one of the more informative single numbers in endocrinology. Superpower makes that kind of testing straightforward: the Superpower Baseline Panel covers 100+ biomarkers from one annual blood draw, and the Advanced Blood Panel adds IGF-1 alongside the rest of the hormone picture. See the full list of growth, hormone, and metabolic biomarkers you can track.